A recent study published in the Lancet and funded by BioMarin Pharmaceutical claims to have found a way to successfully treat — but not cure — achondroplasia, a common form of dwarfism in humans.
As The New York Times reports:
… Read the restThe study has raised hope that the drug, if taken over the course of years, can make life easier for those with the condition, known as achondroplasia, including the distant prospect of alleviating major quality-of-life issues such as back pain and breathing difficulties.
